All In Biotech

Drugs by condition

Drugs approved for lymphoma (non-hodgkin)

Brand-name prescription drugs and biologics whose FDA label lists lymphoma (non-hodgkin) as an approved use. Matched on the label phrases: "large B-cell lymphoma", "follicular lymphoma", "mantle cell lymphoma", "non-Hodgkin".

Last checked: Nov 20, 2026Source: FDA labels (openFDA), Drugs@FDAMethods & limitations

Brand-name drugs approved

33

Still marketed, NDA or BLA

Drug classes

11

Novel drugs

18

New molecular entities and new biologics

In development

40+

Investigational drugs in Phase 2 or 3

Newest approvals

The most recently first-approved brand-name drugs for lymphoma (non-hodgkin).

  • Oxderys (Doxorubicin Hydrochloride) · Avyxa Holdings Nov 9, 2026
  • Beqalzi (Sonrotoclax) · Beone Medicines USA NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanMay 13, 2026
  • Gobarden (Bendamustine Hydrochloride) · Avyxa Holdings Jul 3, 2025
  • Brukinsa (Zanubrutinib) · Beone Medicines USA Accelerated approvalOrphanJun 10, 2025
  • Bortezomib (Bortezomib) · Shilpa Aug 26, 2024

All approved drugs for lymphoma (non-hodgkin), by class

Every marketed NDA or BLA whose current FDA label names this condition in its Indications and Usage section, plus 58 generic labels. A drug can be approved for only part of a condition (one subtype or stage, or as add-on therapy), so check its label.

Kinase Inhibitor (5)

  • Jaypirca Pirtobrutinib · Loxo Oncol · 2023
  • Calquence Acalabrutinib · Astrazeneca · 2017
  • Zydelig Idelalisib · Gilead Sciences INC · 2014
  • Brukinsa Zanubrutinib · Beone Medicines USA · 2025
  • Calquence Acalabrutinib Maleate · Astrazeneca · 2022

Proteasome Inhibitor (3)

Bispecific CD20-directed CD3 T Cell Engager (2)

  • Columvi Glofitamab-Gxbm · Genentech INC · 2023
  • Epkinly Epcoritamab-Bysp · Genmab US, Inc. · 2023

CD20-directed Cytolytic Antibody (2)

  • Gazyva Obinutuzumab · Genentech · 2013
  • Rituxan Rituximab · Genentech · 1997

Programmed Death Receptor-1 Blocking Antibody (1)

  • Keytruda Pembrolizumab · Merck Sharp Dohme · 2014

CD30-directed Immunoconjugate (1)

  • Adcetris Brentuximab Vedotin · Seattle Genetics · 2011

Thalidomide Analog (1)

  • Revlimid Lenalidomide · Bristol Myers Squibb · 2005

Alkylating Drug (1)

  • Leukeran Chlorambucil · Waylis Therap · 1957

Folate Analog Metabolic Inhibitor (1)

  • Jylamvo Methotrexate · Shorla · 2022

Endoglycosidase (1)

  • Rituxan Hycela Rituximab, Hyaluronidase (Human Recombinant) · Genentech INC · 2017

Class not listed in FDA's data (15)

Drugs in development for lymphoma (non-hodgkin)

Investigational drugs FDA has not approved, in active or recent industry-sponsored Phase 2 and 3 trials for this condition. Phase 3 first.

Search the pipeline
  • SintilimabIBI308Phase 321 trials

    Innovent Biologics (Suzhou) Co. Ltd. · Hepatocellular Carcinoma, Solid Tumor, HCC - Hepatocellular Carcinoma

  • AdabelimumabSHR-A2102, SHR2554Phase 320 trials

    Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Advanced Solid Tumors, Prostate Cancer, Advanced Urothelial Carcinoma

  • OrelabrutinibICP-022Phase 311 trials

    Beijing InnoCare Pharma Tech Co., Ltd. · Mantle Cell Lymphoma, Part 1:r/r B-cell Malignancies, Part 2:B-cell Malignancies

  • ZG005Phase 311 trials

    Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Advanced Solid Tumor, Lymphoma, Non-small Cell Lung Cancer

  • APG-2575lisaftoclaxPhase 310 trials

    Ascentage Pharma Group Inc. · CLL/SLL, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

  • FavezelimabMK-4280, MK-4820APhase 39 trials

    Merck & Co. · Melanoma, Carcinoma, Renal Cell, Solid Tumors

  • MK-2140Zilovertamab Vedotin, VLS-101Phase 39 trials

    Merck & Co. · Diffuse Large B-Cell Lymphoma, Lymphoma, Large B-Cell, Diffuse, B-cell Acute Lymphoblastic Leukemia

  • SurovatamigAZD0486, TNB-486Phase 39 trials

    AstraZeneca · B-cell Non-Hodgkin Lymphoma, Large B-cell Lymphoma, Untreated Follicular Lymphoma

  • TucidinostatChidamide, HBI-8000Phase 39 trials

    Chipscreen Biosciences, Ltd. · Relapsed/Refractory PTCLT With at Least One Line of Prior Systemic Therapy, Unresectable or Metastatic Melanoma, Progressive Brain Metastasis

  • BirelentinibDZD8586Phase 37 trials

    Dizal Pharmaceuticals · Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Diffuse Large B-Cell Lymphoma, Immune Thrombocytopenia (ITP)

  • CC-99282BMS-986369, GolcadomidePhase 37 trials

    Bristol Myers Squibb · Lymphoma, Follicular, Large B-cell Lymphoma, Non-Hodgkin Lymphoma

  • OdronextamabREGN1979, OrdsponoPhase 37 trials

    Regeneron · Follicular Lymphoma (FL), Diffuse Large B-Cell Lymphoma (DLBCL), Relapsed/Refractory Follicular Lymphoma

  • XNW5004EZH2iPhase 37 trials

    Evopoint Biosciences Inc. · Relapsed/Refractory Peripheral T Cell Lymphoma, Advanced Prostate Cancer, Follicular Lymphoma, Grade 1

  • MK-1045CN-201Phase 36 trials

    Merck & Co. · Lymphoma, Large B-Cell, Diffuse, Lymphoma, Non-Hodgkin, Lymphoma, Follicular

  • NemtabrutinibMK-1026, ARQ 531Phase 36 trials

    Merck & Co. · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Mantle Cell Lymphoma

  • RocbrutinibLP-168, NWP-775Phase 36 trials

    Guangzhou Lupeng Pharmaceutical Company LTD. · Diffuse Large B-Cell Lymphoma (DLBCL), Mantle Cell Lymphoma (MCL), Mantle Cell Lymphoma

  • SCTB41Phase 36 trials

    Sinocelltech Ltd. · NHL - Non-Hodgkin's Lymphoma, NSCLC (Advanced Non-small Cell Lung Cancer), Advanced Malignant Solid Tumor

  • TacabrutidegBGB-16673Phase 36 trials

    BeOne Medicines (BeiGene) · Chronic Lymphocytic Leukemia, B-cell Malignancy, Small Lymphocytic Lymphoma

  • AbexinostatPCI-24781Phase 35 trials

    Xynomic Pharmaceuticals, Inc. · Lymphoma, Follicular, Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma

  • ICP-248MesutoclaxPhase 35 trials

    Beijing InnoCare Pharma Tech Co., Ltd. · Relapsed or Refractory Mantle Cell Lymphoma (MCL), Acute Myeloblastic Leukemia, Relapsed/Refractory Marginal Zone Lymphoma (MZL)

3 discontinued brand-name drugs whose label still names it

More on lymphoma (non-hodgkin): recruiting trials · published research

Related in hematology and blood cancers: Multiple myeloma · Acute myeloid leukemia · Chronic lymphocytic leukemia · Acute lymphoblastic leukemia · Chronic myeloid leukemia · Hodgkin lymphoma · Myelodysplastic syndromes · Myelofibrosis · Sickle cell disease · Hemophilia

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.